Limits...
Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A - Transl Oncol (2015)

Bottom Line: By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE.Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE.In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: rosadive@inwind.it.

No MeSH data available.


Related in: MedlinePlus

Circulating plasma levels of PAI-1 assayed before (pre) and after (post) treatment with TACE.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562977&req=5

f0010: Circulating plasma levels of PAI-1 assayed before (pre) and after (post) treatment with TACE.

Mentions: To compare the circulating plasma levels of PAI-1 in patients with HCC before and after TACE, we carried out ELISAs on collected peripheral blood samples. We found significantly decreased concentrations of circulating PAI-1 after TACE (34.11 ± 30.5 ng/ml) compared with those before TACE treatment (42.76 ± 25.8 ng/ml, P = .014; Figure 2).


Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A - Transl Oncol (2015)

Circulating plasma levels of PAI-1 assayed before (pre) and after (post) treatment with TACE.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562977&req=5

f0010: Circulating plasma levels of PAI-1 assayed before (pre) and after (post) treatment with TACE.
Mentions: To compare the circulating plasma levels of PAI-1 in patients with HCC before and after TACE, we carried out ELISAs on collected peripheral blood samples. We found significantly decreased concentrations of circulating PAI-1 after TACE (34.11 ± 30.5 ng/ml) compared with those before TACE treatment (42.76 ± 25.8 ng/ml, P = .014; Figure 2).

Bottom Line: By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE.Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE.In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: rosadive@inwind.it.

No MeSH data available.


Related in: MedlinePlus